NCT00103116View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Lung Cancer
Interventions
BIOLOGICAL

autologous dendritic cell cancer vaccine

"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."

Trial Locations (1)

40536-0293

Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Edward Hirschowitz

OTHER

NCT00103116 - Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter